Consistent with the in vitro findings, co-treatment produced a synergistic therapeutic effect in vivo, resulting in a greater reduction of leukemia burden and significantly prolonged survival compared to single-agent treatment in the MLL-AF6 PDX model. The gene discussed is KMT2A; the disease is leukemia.